Trial Profile
Atomoxetine as an adjunct to novel antipsychotic medication in the treatment of cognitive deficits of schizophrenia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Aug 2019
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Therapeutic Use
- 22 Oct 2007 Status changed from recruiting to in progress.
- 05 Nov 2005 New trial record.